Screener / SEC EDGAR /CIK 0001551306 /10-K filed Feb 27, 2026, compared with Mar 3, 2025 /Numbers from the XBRL of the 10-Ks
Nasdaq Health care · Health Services

Progyny, Inc. PGNY

Compare with peers Embed
FY2025 at a glance

Sales up 10.4%, free cash flow up to $191.8M

XBRL, from each 10-K
RevenueStatements
$1.3B from $1.2B in FY2024
FY2017FY2025
Net incomeStatements
$58.5M from $54.3M in FY2024
FY2017FY2025
Free cash flowStatements
$191.8M from $173.7M in FY2024
FY2017FY2025
EPS (diluted)Statements
$0.65 from $0.57 in FY2024
FY2017FY2025
Operating marginStatements
6.6% from 5.8% in FY2024
FY2017FY2025

The latest figures

Price and key numbers

From EDGAR
All key numbers (39)
EPS (ttm)
1.09
Sales (ttm)
1.3B
Net income (ttm)
91.0M
Sales growth
+10.4%
EPS growth
+14.0%
Sales Q/Q
+8.9%
Free cash flow
179.6M
Gross margin
24.9%
Oper. margin
9.4%
Net margin
6.8%
FCF margin
13.4%
R&D / sales
0.7%
Dividend
-
Debt/Eq
-
Curr. ratio
1.93
Cash
116.8M
Op. cash flow (ttm)
207.2M
EBITDA
90.2M
EBITDA margin
7.0%
Quick ratio
1.93
ROIC
12.6%
FCF after stock pay
59.9M
Goodwill / assets
2.7%
Oper. margin low 5y
3.0%
Tax rate
38.7%
Stock pay / sales
10.2%
Shares out.
73.6M
Shares Y/Y
-5.9%
Book / share
5.62
Cash / share
1.59
Sales / share
18.18
Asset turnover
1.98
Days sales out.
62
Sales 3Y CAGR
+17.9%
Sales 5Y CAGR
+30.2%
EPS 3Y CAGR
+29.4%
EPS 5Y CAGR
+6.7%

Hover or tap a number to see the XBRL line item and filing it comes from; click it to open that filing at SEC. What each number means. Looks wrong? Tell us.

Revenue and net income, FY2017 to FY2025

Each fiscal year from its own 10-K · XBRL

Revenue 1.3B +50.6% a year Net income 58.5M
FY2017 revenue 48.6M · RevenueFromContractWithCustomerIncludingAssessedTax, 0001558370-20-002258 FY2017 net income -12.5M · NetIncomeLoss, 0001558370-20-002258 48.6M FY2017 FY2018 revenue 105.4M · RevenueFromContractWithCustomerIncludingAssessedTax, 0001558370-21-002082 FY2018 net income 661K · NetIncomeLoss, 0001558370-21-002082 105.4M FY2018 FY2019 revenue 229.7M · RevenueFromContractWithCustomerIncludingAssessedTax, 0001558370-22-002466 FY2019 net income -8.6M · NetIncomeLoss, 0001558370-22-002466 229.7M FY2019 FY2020 revenue 344.9M · RevenueFromContractWithCustomerExcludingAssessedTax, 0001551306-23-000015 FY2020 net income 46.5M · NetIncomeLoss, 0001551306-23-000015 344.9M FY2020 FY2021 revenue 500.6M · RevenueFromContractWithCustomerExcludingAssessedTax, 0001551306-24-000031 FY2021 net income 65.8M · NetIncomeLoss, 0001551306-24-000031 500.6M FY2021 FY2022 revenue 786.9M · RevenueFromContractWithCustomerExcludingAssessedTax, 0001551306-25-000040 FY2022 net income 30.4M · NetIncomeLoss, 0001551306-25-000040 786.9M FY2022 FY2023 revenue 1.1B · RevenueFromContractWithCustomerExcludingAssessedTax, 0001551306-26-000020 FY2023 net income 62.0M · NetIncomeLoss, 0001551306-26-000020 1.1B FY2023 FY2024 revenue 1.2B · RevenueFromContractWithCustomerExcludingAssessedTax, 0001551306-26-000020 FY2024 net income 54.3M · NetIncomeLoss, 0001551306-26-000020 1.2B FY2024 FY2025 revenue 1.3B · RevenueFromContractWithCustomerExcludingAssessedTax, 0001551306-26-000020 FY2025 net income 58.5M · NetIncomeLoss, 0001551306-26-000020 1.3B FY2025

From XBRL in each 10-K. Hover a bar for the line item and filing. "A year" is the steady yearly growth from FY2017 to FY2025 (8 years).

Growth per share, FY2017 to FY2025

Earnings, book value and free cash flow for each diluted share · 10-K XBRL, every year linked to its filing

Average yearly growth
Earnings per share +48.9% a year FY2018 $0.04 to FY2025 $0.65, 7 years
Book value per share +0.7% a year FY2019 $5.51 to FY2025 $5.74, 6 years
Free cash flow per share +32.0% a year FY2018 $0.31 to FY2025 $2.13, 7 years
Fiscal year toEPS (diluted)Book value / shareFree cash flow / share
Dec 31, 2025 $0.65$5.74$2.13
Dec 31, 2024 $0.57$4.42$1.82
Dec 31, 2023 $0.62$5.50$1.84
Dec 31, 2022 $0.30$3.77$0.77
Dec 31, 2021 $0.66$2.51$0.24
Dec 31, 2020 $0.47$1.69$0.36
Dec 31, 2019 -$0.41$5.51-$0.22
Dec 31, 2018 $0.04-$17.17$0.31
Dec 31, 2017 -$2.37-$17.19-$1.78

Per share means per diluted weighted-average share of the same fiscal year (the count under diluted EPS, put on today's share count after a split). Book value is shareholders' equity at the year end, including any preferred stock; free cash flow is operating cash flow less capital spending. Each tile's rate is the steady yearly growth from the first to the last year it names: the window starts at the oldest year, up to ten years back, with a value above zero.

What the balance sheet holds, per share

Net current asset value and tangible book value, FY2025 · 10-K XBRL, no share price used

Net current asset value, FY2025, in dollars
  • + Current assets $551.8M
  • − All liabilities $226.4M
  • = Net current asset value $325.4M
Per share, year by year
Tangible book value, FY2025, in dollars
  • + Shareholders' equity $516.0M
  • − Goodwill $20.0M
  • − Other intangible assets $6.2M
  • = Tangible book value $489.9M
Per share, year by year

Net current asset value is current assets minus all liabilities (the long-term ones too), so it is what would be left from the short-term assets after everything owed is paid; it is blank for a bank, which reports no current assets. Tangible book value is shareholders' equity minus goodwill and other intangible assets; equity includes any preferred stock. Both are divided by the diluted weighted-average share count of the same fiscal year. Red bars are amounts taken off, or a negative result.

PGNY against Health care peers

Among the 162 companies, the better end on the right. The band holds the middle half; the line is the median.

Ten years, side by side
Sales growth
+4.8%+20.2%
+10.4%80th of 155 · median +10.5%
Net margin
-4.1%15.3%
6.8%77th of 154 · median 6.8%
Return on equity
-5.2%18.5%
22.0%24th of 144 · median 9.2%
Free cash flow margin
2.3%19.2%
13.4%58th of 145 · median 10.0%
PGNY and the 5 peers closest in revenue
CompanyRevenue (ttm)Sales growthFYGross marginttmNet marginttmROEttmFCF marginttmDebt / equitylatest
PGNY Progyny, Inc.$1.3B +10.4%24.9%6.8%22.0%13.4%-
MDGL Madrigal Pharmaceuticals, Inc.$1.4B +432%--10.9%-24.8%-11.8%0.54
HAE Haemonetics Corp$1.4B -2.0%59.6%7.5%11.6%21.6%1.27
GH Guardant Health, Inc.$1.3B +32.9%65.2%-37.9%--18.2%-
SHC Sotera Health Co$1.2B +5.7%54.6%14.1%23.7%11.0%2.91
TECH Bio-Techne$1.2B -0.4%65.8%14.0%7.9%25.1%0.18
All 162 companies in the group

Where each dollar goes

Revenue through the costs to the net profit, from the 10-K income statement and revenue by product

From $500.6M of sales to $65.8M of profit FY2021

  • Fertility benefit services revenue $355.6M
  • Pharmacy benefit services revenue $145.0M
Revenue to Gross profit: $112.1MRevenue to Cost of revenue: $388.5MGross profit to Operating profit: $32.3MGross profit to Operating expenses: $79.8MOperating profit to Net profit: $32.3MOther income to Net profit: $33.4M Revenue: $500.6M REVENUE $500.6M +45% Y/Y Gross profit: $112.1M · 22% margin GROSS PROFIT $112.1M 22% margin · +60% Y/Y Cost of revenue: $388.5M · 78% of revenue COST OF REVENUE $388.5M 78% of revenue Operating profit: $32.3M · 6% margin OPERATING PROFIT $32.3M 6% margin · +287% Y/Y Other income: $33.4M · 7% of revenue OTHER INCOME $33.4M 7% of revenue Operating expenses: $79.8M · 16% of revenue OPERATING EXPENSES $79.8M 16% of revenue Net profit: $65.8M · 13% margin NET PROFIT $65.8M 13% margin · +42% Y/Y

From $786.9M of sales to $30.4M of profit FY2022

  • Fertility benefit services revenue $510.1M
  • Pharmacy benefit services revenue $276.8M
Revenue to Gross profit: $167.3MRevenue to Cost of revenue: $619.6MGross profit to Operating profit: $23.3MGross profit to Operating expenses: $144.0MOperating profit to Net profit: $23.3MOther income to Net profit: $7.0M Revenue: $786.9M REVENUE $786.9M +57% Y/Y Gross profit: $167.3M · 21% margin GROSS PROFIT $167.3M 21% margin · +49% Y/Y Cost of revenue: $619.6M · 79% of revenue COST OF REVENUE $619.6M 79% of revenue Operating profit: $23.3M · 3% margin OPERATING PROFIT $23.3M 3% margin · −28% Y/Y Other income: $7.0M · 1% of revenue OTHER INCOME $7.0M 1% of revenue Operating expenses: $144.0M · 18% of revenue OPERATING EXPENSES $144.0M 18% of revenue Net profit: $30.4M · 4% margin NET PROFIT $30.4M 4% margin · −54% Y/Y

From $1.1B of sales to $62.0M of profit FY2023

  • Fertility benefit services revenue $676.3M
  • Pharmacy benefit services revenue $412.3M
Revenue to Gross profit: $238.8MRevenue to Cost of revenue: $849.8MGross profit to Operating profit: $62.2MGross profit to Operating expenses: $176.6MOperating profit to Net profit: $62.0M Revenue: $1.1B REVENUE $1.1B +38% Y/Y Gross profit: $238.8M · 22% margin GROSS PROFIT $238.8M 22% margin · +43% Y/Y Cost of revenue: $849.8M · 78% of revenue COST OF REVENUE $849.8M 78% of revenue Operating profit: $62.2M · 6% margin OPERATING PROFIT $62.2M 6% margin · +166% Y/Y Operating expenses: $176.6M · 16% of revenue OPERATING EXPENSES $176.6M 16% of revenue Net profit: $62.0M · 6% margin NET PROFIT $62.0M 6% margin · +104% Y/Y

From $1.2B of sales to $54.3M of profit FY2024

  • Fertility benefit services revenue $729.6M
  • Pharmacy benefit services revenue $437.7M
Revenue to Gross profit: $253.4MRevenue to Cost of revenue: $913.9MGross profit to Operating profit: $67.5MGross profit to Operating expenses: $185.9MOperating profit to Net profit: $38.6MOperating profit to Tax: $28.9MOther income to Net profit: $15.7M Revenue: $1.2B REVENUE $1.2B +7% Y/Y Gross profit: $253.4M · 22% margin GROSS PROFIT $253.4M 22% margin · +6% Y/Y Cost of revenue: $913.9M · 78% of revenue COST OF REVENUE $913.9M 78% of revenue Operating profit: $67.5M · 6% margin OPERATING PROFIT $67.5M 6% margin · +8% Y/Y Other income: $15.7M · 1% of revenue OTHER INCOME $15.7M 1% of revenue Operating expenses: $185.9M · 16% of revenue OPERATING EXPENSES $185.9M 16% of revenue Net profit: $54.3M · 5% margin NET PROFIT $54.3M 5% margin · −12% Y/Y Tax: $28.9M · 2% of revenue TAX $28.9M 2% of revenue

From $1.3B of sales to $58.5M of profit FY2025

  • Fertility benefit services revenue $830.9M
  • Pharmacy benefit services revenue $457.7M
Revenue to Gross profit: $304.5MRevenue to Cost of revenue: $984.2MGross profit to Operating profit: $85.3MGross profit to Operating expenses: $219.2MOperating profit to Net profit: $58.5MOperating profit to Tax & other: $26.8MOperating expenses to R&D: $9.5MOperating expenses to Sales, admin & other: $209.7M Revenue: $1.3B REVENUE $1.3B +10% Y/Y Gross profit: $304.5M · 24% margin GROSS PROFIT $304.5M 24% margin · +20% Y/Y Cost of revenue: $984.2M · 76% of revenue COST OF REVENUE $984.2M 76% of revenue Operating profit: $85.3M · 7% margin OPERATING PROFIT $85.3M 7% margin · +26% Y/Y Operating expenses: $219.2M · 17% of revenue OPERATING EXPENSES $219.2M 17% of revenue Net profit: $58.5M · 5% margin NET PROFIT $58.5M 5% margin · +8% Y/Y Tax & other: $26.8M · 2% of revenue TAX & OTHER $26.8M 2% of revenue R&D: $9.5M · 1% of revenue R&D $9.5M 1% of revenue Sales, admin & other: $209.7M · 16% of revenue SALES, ADMIN & OTHER $209.7M 16% of revenue

Where each $100 of sales went

FY2021
FY2022
FY2023
FY2024
FY2025
  • Cost of revenue
  • Sales, admin & other
  • Net profit
  • Tax, less other income
  • R&D

Band widths are the money. Gross profit is revenue less cost of revenue; operating expenses are gross profit less operating profit; R&D is from the income statement and the rest of the operating expenses is everything else; tax includes interest and other items when they are small. Y/Y is the change from the fiscal year before. Revenue by part only for the years in the last two 10-Ks' segment tables. The full income statement

Where the return on equity comes from

DuPont: net margin × asset turnover × leverage, FY2025 against FY2020 · 10-K XBRL, year-end balances

Return on equity 11.3% FY2020: 27.8% net income ÷ equity
Net margin 4.5% FY2020: 13.5% profit per $ of sales: 58.5M ÷ 1.3B
Asset turnover 1.74× FY2020: 1.36× sales per $ of assets: 1.3B ÷ 742.4M
Leverage 1.44× FY2020: 1.52× assets per $ of equity: 742.4M ÷ 516.0M

The three parts multiply to the return on equity. A higher return from leverage alone means more debt or less equity (buybacks shrink equity), not a better business. Year-end balances as filed, not averages, so each number is one line of one 10-K; hover a box for its XBRL tags.

Profitability

  • Net margin above the peer median
    6.8% vs 6.8%
  • Gross margin up over 5 years
    20.3% → 23.6%
  • Return on equity above 15%
    22.0%
  • A profit in 7 of 9 years
Net margin, FY2017 to FY2025: -25.6% to 4.5%

Cash and shareholders

  • Free cash flow positive in 7 of 9 years
    $191.8M last year
  • Share count down over 5 years
    −9.3%
  • Cash from operations above net income
    $210.2M vs $58.5M
Free cash flow, FY2017 to FY2025: -10.1M to 191.8M

Each tick is a fact with a fixed rule (on /methodology), not a score or advice. A check without the numbers it needs is left out.

Income statement, balance sheet and cash flow

Statements · XBRL, each 10-K and 10-Q

From EDGAR

PGNY's income statement, balance sheet and cash flow as reported to the SEC in XBRL, one column per fiscal year, the last 9. Hover a number to see the line item and filing it comes from. Where a company changed how it tags a line, the first tag it reported for that period is used. A number looks wrong? Tell us.

Revenue1.3B
FY2017: 48.6MFY2018: 105.4MFY2019: 229.7MFY2020: 344.9MFY2021: 500.6MFY2022: 786.9MFY2023: 1.1BFY2024: 1.2BFY2025: 1.3B FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Net income58.5M
FY2017: -12.5MFY2018: 661KFY2019: -8.6MFY2020: 46.5MFY2021: 65.8MFY2022: 30.4MFY2023: 62.0MFY2024: 54.3MFY2025: 58.5M FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Free cash flow191.8M
FY2017: -10.1MFY2018: 1.7MFY2019: -4.5MFY2020: 35.2MFY2021: 23.9MFY2022: 77.2MFY2023: 185.2MFY2024: 173.7MFY2025: 191.8M FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Free cash flow after stock pay59.9M
FY2017: -11.6MFY2018: -1.3MFY2019: -9.6MFY2020: 22.3MFY2021: -9.8MFY2022: -23.6MFY2023: 62.6MFY2024: 45.6MFY2025: 59.9M FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
EPS (diluted)0.65
FY2017: -2.37FY2018: 0.04FY2019: -0.41FY2020: 0.47FY2021: 0.66FY2022: 0.30FY2023: 0.62FY2024: 0.57FY2025: 0.65 FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Diluted shares89.9M
FY2017: 5.7MFY2018: 5.5MFY2019: 20.7MFY2020: 99.1MFY2021: 100.4MFY2022: 100.0MFY2023: 100.7MFY2024: 95.4MFY2025: 89.9M FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025

Revenue by product or service

year to Dec 31, 2025
RevenueSharevs year before
Fertility benefit services revenue 830.9M64.5% +13.9%
Pharmacy benefit services revenue 457.7M35.5% +4.6%

10-K 0001551306-26-000020, segment and revenue notes (XBRL).

Income statement

From EDGAR
FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Revenue48.6M105.4M229.7M344.9M500.6M786.9M1.1B1.2B1.3B
Cost of revenue41.2M86.0M184.2M274.8M388.5M619.6M849.8M913.9M984.2M
Gross profit7.4M19.4M45.5M70.1M112.1M167.3M238.8M253.4M304.5M
R&D--------9.5M
SG&A14.1M15.6M23.9M46.7M59.6M98.3M117.1M122.0M147.1M
Operating income-11.0M-3.5M9.7M8.3M32.3M23.3M62.2M67.5M85.3M
Interest expense542K505K176K------
Pretax income-12.5M-6.9M-8.6M8.7M32.4M24.4M70.7M83.2M95.4M
Income tax-3K-1.8M12K-37.8M-33.3M-5.9M8.7M28.9M36.9M
Net income-12.5M661K-8.6M46.5M65.8M30.4M62.0M54.3M58.5M
EPS (diluted)-2.370.04-0.410.470.660.300.620.570.65
Diluted shares5.7M5.5M20.7M99.1M100.4M100.0M100.7M95.4M89.9M
Depreciation & amortization1.6M1.9M2.1M1.9M1.3M1.6M2.3M3.2M4.9M
EBITDA-9.4M-1.6M11.8M10.3M33.6M24.9M64.5M70.6M90.2M
Gross margin15.2%18.4%19.8%20.3%22.4%21.3%21.9%21.7%23.6%
Operating margin-22.7%-3.3%4.2%2.4%6.5%3.0%5.7%5.8%6.6%
Net margin-25.6%0.6%-3.7%13.5%13.1%3.9%5.7%4.7%4.5%
Revenue growth-+117%+118%+50.1%+45.2%+57.2%+38.3%+7.2%+10.4%
EPS growth--to a loss-+40.4%-54.5%+107%-8.1%+14.0%

Cash flow

From EDGAR
FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Operating cash flow-9.5M2.3M-1.5M36.2M26.0M80.4M188.8M179.1M210.2M
Capital spending612K579K3.0M1.0M2.1M3.2M3.6M5.4M18.4M
Free cash flow-10.1M1.7M-4.5M35.2M23.9M77.2M185.2M173.7M191.8M
Stock-based pay (added back)1.6M3.0M5.1M12.8M33.7M100.7M122.6M128.1M131.9M
Free cash flow after stock pay-11.6M-1.3M-9.6M22.3M-9.8M-23.6M62.6M45.6M59.9M
Buybacks-1.2M185K--00300.3M81.7M
Acquisitions-----005.3M9.3M
Investing cash flow-612K1.9M-2.8M-40.0M8.8M-43.9M-200.5M195.8M-159.0M
Financing cash flow11.8M-8.7M84.5M-6.2M-13.7M-7.9M-11.1M-309.9M-99.4M

Stock-based pay and leases

From EDGAR
FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Stock-based pay (expense)1.6M3.0M5.1M12.8M33.7M100.7M122.6M128.1M131.9M
Stock-based pay / revenue3.2%2.8%2.2%3.7%6.7%12.8%11.3%11.0%10.2%
Operating lease cash paid---800K1.3M1.3M1.3M2.3M3.1M
Right-of-use assets--9.5M8.7M7.8M6.9M17.6M17.3M25.0M
Operating lease liabilities--9.9M9.5M8.7M7.7M19.4M19.3M27.7M

From SEC's XBRL company facts (data.sec.gov). EBITDA = operating income + depreciation and amortization; free cash flow = operating cash flow - capital spending; total debt = long-term debt (with its current part) + short-term borrowings. Stock-based pay and leases are shown as the company reports them; Tickdelta does not take them out of earnings or add leases to debt. Click a number to open the filing in SEC's Inline XBRL viewer, where you can click the same number to see how it is tagged. Values a company later revised show as revised; the Revised numbers tab lists the changes.

Sources

Every figure is from the company's XBRL filed with each 10-K and 10-Q (data.sec.gov). Hover a number for its line item; click it to open the filing.

Also

Company numbers: the figures the company reports beyond the statements. Peers: ten years, side by side.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/PGNY/export.csv") into a cell.

Next:Peers in numbers
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.